Evidence map›Paper›PMID 31190687›Full record

ArticleJournal of the Royal Statistical Society. Series C, Applied statistics2019

AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose finding trials.

Jiaying Lyu, Yuan Ji, Naiqing Zhao, Daniel V T Catenacci

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Royal Statistical Society. Series C, Applied statistics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials.Journal of the Royal Statistical Society. Series C, Applied statistics · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Jiaying LyuFudan University, Shanghai, People's Republic of China.
Yuan JiNorthShore University HealthSystem, Evanston, and University of Chicago, USA.
Naiqing ZhaoFudan University, Shanghai, People's Republic of China.
Daniel V T CatenacciUniversity of Chicago, USA.
Fudan University · CNNorthShore University HealthSystem · USUniversity of Chicago · US

Funding

PANGEA: Personalized Antibodies for GastroEsophageal Adenocarcinoma Pilot TrialK23CA178203 · NCI · UNIVERSITY OF CHICAGO · PI CATENACCI, DANIEL · 2014 to 2016
$507k
NCI NIH HHS K23 CA178203
6 · The paper itself

Abstract

We propose a flexible design for the identification of optimal dose combinations in dual-agent dose finding clinical trials. The design is called AAA, standing for three adaptations: adaptive model selection, adaptive dose insertion and adaptive cohort division. The adaptations highlight the need and opportunity for innovation for dual-agent dose finding and are supported by the numerical results presented in the proposed simulation studies. To our knowledge, this is the first design that allows for all three adaptations at the same time. We find that AAA enhances the chance of finding the optimal dose combinations and shortens the trial duration. A clinical trial is being planned to apply the AAA design and a Web tool is being developed for both statisticians and non-statisticians.

Indexed as

Adaptive cohort divisionBayesian inferenceDose combinationHierarchical modelsMarkov chain Monte Carlo simulationPhase I–II clinical trial

Identifiers

PMID31190687
PMCPMC6561465
OpenAlexW2625526798

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.